Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – IT Business Net
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine…
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…
-
Noosa News10 hours agoTwo teenagers and two adults rushed to hospital in life-threatening conditions after shocking Lawnton house fire
-
Noosa News12 hours agoA secret scheme and plans to expel former leaders — here’s what we’ve heard from Queensland’s inquiry into the CFMEU
-
Noosa News11 hours agoFatal traffic crash, Noosa – Sunshine Coast
-
Business11 hours agoTop brokers name 3 ASX shares to buy next week 23 November 2025